Federal Circuit Strikes Down More Myriad Cancer Test Patents
The Federal Circuit ruled Wednesday that three Myriad Genetics Inc. breast cancer test patents are invalid for claiming patent-ineligible subject matter, another major setback for the company after the U.S. Supreme Court ruled last year that it could not patent human genes.In a win for Ambry Genetics Corp., which makes rival breast cancer tests that Myriad accused of…